Hoshen Moshe B, Benis Arriel, Keyes Katherine M, Zoëga Helga
Clalit Research Institute, Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel.
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Pharmacoepidemiol Drug Saf. 2016 Jun;25(6):652-60. doi: 10.1002/pds.3962. Epub 2016 Jan 29.
Diagnosis of children with attention-deficit/hyperactivity disorder (ADHD) is increasing. The present study sought to identify characteristics and medication treatment patterns of children with ADHD and compare them by relative age in class, sex, ethnicity, family size, sibling order, and other socioeconomic status, as well as find trends in disparity of pharmacotherapy.
This study was based on data from 1 013 149 Clalit Health Services members aged 6-17 years during 2006-2011. Centrally acting sympathomimetic drug purchases were compared according to children's estimated relative age in class; youngest third (born August to November), middle third (born April to July), and oldest third (born December to March). Treatment trends were determined and compared according to sociodemographic and family-related factors.
The overall prevalence of stimulant use in the population was 2.6% in 2006 and 4.9% in 2011. The annual incidence of stimulant use increased from 0.75% to 1.36%, rising more sharply among children in the older age groups (≥12) than among younger ones. Moreover, the youngest third of children in class was more likely to use medication than the oldest third (risk ratio (RR) 1.17, confidence interval (CI) 1.12-1.23) or the middle third (RR 1.06, CI 1.01-1.11). Of the different ethnic sectors, incidence of stimulant use was highest among general Jewish (1.8% in 2011) and lowest among Arabs (0.37% in 2011).
The use of stimulant medication is growing among children in Israel. Although the overall use does not exceed the estimated prevalence of ADHD among children, the appropriateness of prescribing to the Israeli pediatric population, especially to the youngest children in class, may be questionable. Copyright © 2016 John Wiley & Sons, Ltd.
被诊断患有注意力缺陷多动障碍(ADHD)的儿童数量正在增加。本研究旨在确定ADHD儿童的特征和药物治疗模式,并按班级相对年龄、性别、种族、家庭规模、出生顺序及其他社会经济状况对其进行比较,同时找出药物治疗方面的差异趋势。
本研究基于2006 - 2011年期间1013149名年龄在6 - 17岁的克拉利特健康服务机构成员的数据。根据儿童在班级中的估计相对年龄比较中枢性拟交感神经药物的购买情况;年龄最小的三分之一(8月至11月出生)、中间三分之一(4月至7月出生)和年龄最大的三分之一(12月至3月出生)。根据社会人口统计学和家庭相关因素确定并比较治疗趋势。
2006年人群中兴奋剂使用的总体患病率为2.6%,2011年为4.9%。兴奋剂使用的年发病率从0.75%增至1.36%,在年龄较大组(≥12岁)儿童中增长幅度大于较小组儿童。此外,班级中年龄最小的三分之一儿童比年龄最大的三分之一(风险比(RR)1.17,置信区间(CI)1.12 - 1.23)或中间三分之一(RR 1.06,CI 1.01 - 1.11)更有可能使用药物。在不同种族群体中,兴奋剂使用发病率在一般犹太人群中最高(2011年为1.8%),在阿拉伯人群中最低(2011年为0.37%)。
以色列儿童中兴奋剂药物的使用正在增加。尽管总体使用情况未超过儿童中ADHD的估计患病率,但对以色列儿科人群,尤其是班级中年龄最小的儿童开药的合理性可能值得怀疑。版权所有© 2016约翰威立父子有限公司。